McLeod Ian 4

4 · Anika Therapeutics, Inc. · Filed Mar 23, 2026

AI-generated summary of this filing

Updated Mar 23, 2026

Anika (ANIK) SVP Ian McLeod Receives Equity Awards

What Happened

Ian McLeod, SVP, Chief Accounting Officer & Treasurer of Anika Therapeutics (ANIK), was granted a total of 41,954 derivative awards on March 19, 2026. The awards consist of two restricted stock unit (RSU) grants (13,097 and 11,194 units) and a Premium Priced Stock Appreciation Right (PPSAR) for 17,663 units. The awards were granted at an acquisition price of $0 (standard for equity awards); no immediate cash changed hands.

Key Details

Transaction date: 2026-03-19; Form 4 filed 2026-03-23 (filed within the required two-business-day window).
Award breakdown: 13,097 RSUs, 11,194 RSUs, and 17,663 PPSAR units (total 41,954).
Acquisition price reported: $0 (grant/award).
Vesting notes:
- RSUs: each RSU represents the right to receive one share (or cash equivalent) on vesting (Footnote F1).
- One RSU award vests in three equal annual installments beginning March 19, 2027 (F2).
- One RSU award vests fully on March 19, 2029 (F3).
- PPSAR: premium-priced SAR with an exercise price equal to 110% of the fair market value on the grant date; vests in three equal annual installments beginning March 19, 2027 and payable in cash, shares, or a mix at the company’s discretion (F4).
Shares owned after the transaction: not specified in the provided filing details.

Context

RSUs are not an immediate purchase — they are contingent rights to receive stock (or cash) on future vesting dates, so they do not necessarily signal an immediate market action.
A PPSAR pays out only if the stock price exceeds the specified premium exercise price (here, 110% of the grant-date fair market value); it is an equity-based upside-only award rather than an outright share grant.
These are company-granted awards (code A on Form 4) rather than open-market purchases or sales; they reflect compensation/equity incentive decisions rather than direct insider stock buying or selling.

Form 4

Period: 2026-03-19

SVP, CAO & Treasurer

Transactions

Award
Restricted Stock Unit
[F1][F2]
2026-03-19+13,097→ 13,097 total
→ Common Stock (13,097 underlying)
Award
Restricted Stock Unit
[F1][F3]
2026-03-19+11,194→ 11,194 total
→ Common Stock (11,194 underlying)
Award
Premium Priced Stock Appreciation Rights
[F4]
2026-03-19+17,663→ 17,663 total
Exercise: $15.60Exp: 2036-03-19→ Common Stock (17,663 underlying)

Footnotes (4)

[F1]Each Restricted Stock Unit ("RSU") represents the contingent right to receive, at the Issuer's discretion, one share of the Issuer's common stock, or the cash equivalent of the closing price of one share of the Issuer's common stock, on each vest date, in accordance with the Anika Therapeutics, Inc. 2017 Omnibus Incentive Plan, as amended (the "2017 Plan"), and the applicable award agreement.
[F2]Vests in three equal annual installments, with the first installment vesting on March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date.
[F3]Vests fully on March 19, 2029, subject to the Reporting Person's continuous service to the Issuer as of such date.
[F4]Represents a Premium Priced Stock Appreciation Right ("PPSAR") granted under the 2017 Plan. The PPSAR exercise price per share is equal to 110% of the Fair Market Value (as defined in the 2017 Plan) of a share of common stock on the Grant Date. The PPSAR vests in three equal annual installments beginning March 19, 2027, subject to the Reporting Person's continuous service to the Issuer on each such date. The PPSAR is payable in cash, shares of common stock, or a combination thereof, at the Issuer's discretion, in accordance with the 2017 Plan, as amended, and the applicable award agreement.

Signature

/s/ Ian McLeod|2026-03-23

1 file